{"status": "Ok", "redirect_url": "https://www.globenewswire.com/news-release/2026/06/08/3308124/29489/en/AIM-ImmunoTech-Reports-Positive-Mid-Year-Interim-Clinical-Progress-from-Phase-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-.html", "message": "News view counter 785913 successfully enlarged"}